[89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma

Watchful waiting (WW) can be considered for patients with metastatic clear-cell renal cell carcinoma (mccRCC) with good or intermediate prognosis, especially those with

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2023-02, Vol.29 (3), p.592-601
Hauptverfasser:	Verhoeff, Sarah R, Oosting, Sjoukje F, Elias, Sjoerd G, van Es, Suzanne C, Gerritse, Sophie L, Angus, Lindsay, Heskamp, Sandra, Desar, Ingrid M E, Menke-van der Houven van Oordt, C Willemien, van der Veldt, Astrid A M, Arens, Anne I J, Brouwers, Adrienne H, Eisses, Bertha, Mulders, Peter F A, Hoekstra, Otto S, Zwezerijnen, Gerben J C, van der Graaf, Winette T A, Aarntzen, Erik H J G, Oyen, Wim J G, van Herpen, Carla M L
Format:	Artikel
Sprache:	eng
Schlagworte:	Carcinoma, Renal Cell - diagnostic imaging Carcinoma, Renal Cell - therapy Fluorodeoxyglucose F18 - therapeutic use Humans Positron Emission Tomography Computed Tomography Prognosis Radioisotopes - therapeutic use Radiopharmaceuticals - therapeutic use Watchful Waiting Zirconium
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Watchful waiting (WW) can be considered for patients with metastatic clear-cell renal cell carcinoma (mccRCC) with good or intermediate prognosis, especially those with
ISSN:	1078-0432 1557-3265
DOI:	10.1158/1078-0432.CCR-22-0921